LB PharmaceuticalsCommon Stock Accounts Payable

LB PharmaceuticalsCommon Stock (LBRX) currently reports a accounts payable of $3.5M as of June 2026. That compares with $640K in the prior-year period — up 449.8% year over year. Use the charts on this page to explore LB PharmaceuticalsCommon Stock's accounts payable history and peer comparisons.

LB PharmaceuticalsCommon Stock's accounts payable increased from $640K to $3.5M — a 449.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

LB PharmaceuticalsCommon Stock reported $3.5M in accounts payable as of June 2026. That compares with $640K in the prior-year period — up 449.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $3.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for LB PharmaceuticalsCommon Stock, and consider following LBRX for alerts when major investors trade the stock.

LB PharmaceuticalsCommon Stock is classified in the Healthcare sector. On accounts payable, it currently shows $3.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LBRX with unrelated industries.